Study population and setting
Description of clinical outcomes of 53 patients with severe COVID-19 who received Remdesivir through a Gilead compassionate use protocol. Patients from multiple countries were included. 40 patients (75%) were men; the median age was 64 years (interquartile range, 48 to 71); 30 patients (57%) were intubated at baseline.
Summary of Main Findings
Over a median follow-up of 18 days after receiving the first dose of Remdesivir, 36 of 53 patients (68%) showed an improvement in oxygen support, whereas 8 of 53 patients (15%) showed worsening. By 28 days of follow-up, the cumulative incidence of clinical improvement, as defined by either a decrease of 2 points or more on the six-point ordinal scale or live discharge, was 84% (95% confidence interval [CI], 70 to 99). Seven of the 53 patients (13%) died after the completion of Remdesivir, and 12 patients (23%) had serious adverse events.
First published descriptive study of Remdesivir.
This is a small case series with no comparator making it difficult to know if patients’ clinical outcomes were affected by Remdesivir. There were no defined endpoints; rather a description of the patient’s symptoms and laboratory data were given before and after the use of Remdesivir.
This paper adds to the current minimal published descriptive data on the use of Remdesivir.